Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Essai clinique de la solution de nébuliseur de molgramostim inhalé dans la protéinose alvéolaire pulmonaire auto-immune (aPAP) (IMPALA-2)

2 novembre 2026 mis à jour par: Savara Inc.

Un essai clinique randomisé, en double aveugle et contrôlé par placebo portant sur une solution de nébuliseur de molgramostim inhalé une fois par jour chez des sujets adultes atteints de protéinose alvéolaire pulmonaire auto-immune (aPAP)

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

This is an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial in adult subjects who are diagnosed with aPAP.

An aPAP diagnosis should be confirmed by a Granulocyte-macrophage colony stimulating factor (GM-CSF) auto-antibody test result, and history of PAP based on either high resolution computed tomography, lung biopsy, or bronchoalveolar lavage cytology, should be available.

The trial consists of a 6-week screening period, a 48-week randomized, double-blind treatment period, a 96-week open-label treatment period, and a conditional 4-week safety follow-up period. The maximum treatment duration will be 145 weeks and the maximum trial duration will be 156 weeks. During the trial, whole lung lavage will be allowed as rescue treatment in case of worsening of aPAP.

Type d'étude

Interventionnel

Inscription (Réel)

164

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Allemagne, 69126
        • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg
    • Bavaria
      • Muenchen-Gauting, Bavaria, Allemagne, 82131
        • Asklepios Fachkliniken Muenchen-Gauting
    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Allemagne, 45239
        • Ruhrlandklinik Westdeutsches Lungenzentrum
    • New South Wales
      • Camperdown, New South Wales, Australie, 2050
        • Royal Prince Alfred Hospital
      • Westmead, New South Wales, Australie, 2145
        • Westmead Hospital
    • Brussels Capital
      • Brussels, Brussels Capital, Belgique, 1070
        • Hôpital Erasme
    • Vlaams Brabant
      • Leuven, Vlaams Brabant, Belgique, 3000
        • UZ Leuven - Campus Gasthuisberg - Pneumologie
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N1
        • University of Calgary
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
        • St Joseph's Healthcare Hamilton Research
    • Quebec
      • Québec, Quebec, Canada, G1V 4G5
        • University Institute of Cardiology and Respirology of Quebec
      • Seoul, Corée du Sud, 03080
        • Seoul National University Hospital
      • Seoul, Corée du Sud, 05505
        • Asan Medical Center
      • Seoul, Corée du Sud, 06351
        • Samsung Medical Center
      • Seoul, Corée du Sud, 03722
        • Severance Hospital - Yonsei University Health System - Pulmonary
    • Catalonia
      • Barcelona, Catalonia, Espagne, 08907
        • Hospital Universitario de Bellvitge
    • Auvergne-Rhône-Alpes
      • Bron, Auvergne-Rhône-Alpes, France, 69500
        • Hôpital Louis Pradel
    • Brittany Region
      • Rennes, Brittany Region, France, 35033
        • CHU Pontchaillou
      • Athens, Grèce, 12462
        • Attikon University Hospital
      • Dublin, Irlande, DO4 T6F4
        • St. Vincent's University Hospital
    • Lombardy
      • Pavia, Lombardy, Italie, 27100
        • Fondazione IRCCS Policlinico San Matteo
      • Nagakute, Japon, 480-1195
        • Aichi Medical University Hospital
    • Chiba
      • Chiba, Chiba, Japon, 260-8677
        • Chiba University Hospital - Respiratory Medicine
    • Hokkaidô
      • Sapporo, Hokkaidô, Japon, 060-8648
        • Hokkaido University Hospital
    • Kanagawa
      • Yokohama, Kanagawa, Japon, 236-0051
        • Kanagawa Cardiovascular and Respiratory Center
    • Kumamoto
      • Kumamoto, Kumamoto, Japon, 860-8556
        • Kumamoto University Hospital
    • Miyagi
      • Sendai, Miyagi, Japon, 980-8574
        • Tohoku University Hospital - Respiratory Tract Medicine
    • Osaka
      • Sakai, Osaka, Japon, 591-8555
        • National Hospital Organization Kinki-Chuo Chest medical Center
    • Saitama
      • Saitama, Saitama, Japon, 330-8553
        • Saitama Red Cross Hospital
    • Tokyo
      • Mitaka, Tokyo, Japon, 181-8611
        • Kyorin University Hospital
    • Lisbon District
      • Lisbon, Lisbon District, Le Portugal, 1769-001
        • Hospital Pulido Valente
    • Porto District
      • Porto, Porto District, Le Portugal, 4200-319
        • Hospital São João
    • Utrecht
      • Nieuwegein, Utrecht, Pays-Bas, 3435CM
        • St Antonius Hospital
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Pologne, 01-138
        • Instytut Gruzlicy i Chorob Pluc
    • Bucharest
      • Bucharest, Bucharest, Roumanie, 050159
        • Institutul de Pneumoftiziologie "Marius Nasta"
    • London
      • London, London, Royaume-Uni, SW3 6NP
        • Royal Brompton and Harefield NHS Foundation Trust
    • Ankara
      • Ankara, Ankara, Turquie (Türkiye), 6010
        • Health Sciences University Gulhane Training and Research Hospital
    • Istanbul
      • Istanbul, Istanbul, Turquie (Türkiye), 34020
        • Yedikule Chest Disease and Surgery Training and Research Hospital
    • İzmir
      • Bornova, İzmir, Turquie (Türkiye), 35100
        • Ege University Hospital - Department of Pulmonology
    • Arkansas
      • Little Rock, Arkansas, États-Unis, 72205
        • University Of Arkansas For Medical Services
    • California
      • Los Angeles, California, États-Unis, 90095
        • UCLA David Geffen School of Medicine
    • Colorado
      • Denver, Colorado, États-Unis, 80206
        • National Jewish Health
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06520
        • Yale University
    • Florida
      • Gainesville, Florida, États-Unis, 32610
        • University of Florida Health
    • Georgia
      • Atlanta, Georgia, États-Unis, 30322
        • Emory University
    • Illinois
      • Maywood, Illinois, États-Unis, 60153
        • Loyola University
    • Maryland
      • Baltimore, Maryland, États-Unis, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, États-Unis, 63110
        • Washington University in St. Louis
    • North Carolina
      • Durham, North Carolina, États-Unis, 27710
        • Duke University Medical Center
      • Raleigh, North Carolina, États-Unis, 27610
        • Wake Med Health & Hospital
    • Ohio
      • Cincinnati, Ohio, États-Unis, 45229-3039
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, États-Unis, 44195
        • Cleveland Clinic
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • University of Pennsylvania Perelman School of Medicine - Pulmonology
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • University of Pittsburgh
    • Texas
      • Dallas, Texas, États-Unis, 75390
        • UT Southwestern Medical Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  1. Subject must be ≥18 years of age, at the time of signing the informed consent (≥20 in Japan).

  2. A serum anti-GM-CSF autoantibody test result confirming autoimmune PAP.

  3. History of PAP, based on examination of a lung biopsy, bronchoalveolar lavage (BAL) cytology, or a high-resolution computed tomogram (HRCT) of the chest.

  4. A diffusing capacity for carbon monoxide of 70% predicted or lower adjusted for hemoglobin (%DLCOadj) at the screening and baseline visits.

  5. Change in %DLCO adj of <15% points during the screening period.

  6. Demonstrated functional impairment in the treadmill exercise test (defined as a peak metabolic equivalent (MET) ≤8).

  7. Willing and able to come off supplemental oxygen use prior to and during the treadmill exercise test, the DLCO assessment, and the arterial blood gas sampling.

  8. Resting oxygen saturation (SpO2) >85% during 15 minutes without use of supplemental oxygen at the screening visits.

  9. Male or female

  10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male subjects: Males agreeing to use condoms during and until 30 days after last dose of trial treatment, or males having a female partner who is using adequate contraception as described below.
    2. Female subjects: Females who have been post-menopausal for >1 year, or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with <1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence*), during and until 30 days after last dose of trial treatment. Females of childbearing potential must have a negative serum pregnancy test at the screening visits, and a negative urine pregnancy test at Baseline visit (Visit 3) and must not be lactating.
  11. Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  12. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the Investigator.

Exclusion Criteria:

  1. Diagnosis of hereditary or secondary PAP, or a metabolic disorder of surfactant production.
  2. Whole lung lavage (WLL) performed within 3 months prior to baseline.
  3. Requirement for WLL at screening or baseline.
  4. GM-CSF treatment within 6 months prior to baseline.
  5. Treatment with rituximab within 6 months prior to baseline.
  6. Treatment with plasmapheresis within 6 weeks prior to baseline.
  7. Treatment with any investigational medicinal product within 5 half-lives or 3 months (whichever is longer) prior to baseline.
  8. Previously randomized in this trial.
  9. History of allergic reactions to GM-CSF or any of the excipients in the nebulizer solution.
  10. Inflammatory or autoimmune disease of a severity that necessitates significant (e.g. more than 10 mg/day systemic prednisolone) immunosuppression.
  11. Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product.
  12. History of, or present, myeloproliferative disease or leukemia.
  13. Apparent pre-existing concurrent pulmonary fibrosis.
  14. Acute or unstable cardiac or pulmonary disease that may be aggravated by exercise.
  15. Known active infection (viral, bacterial, fungal, or mycobacterial) that may affect the efficacy evaluation in the trial.
  16. Physical disability or other condition that precludes safe and adequate exercise testing.
  17. Any other serious medical condition which in the opinion of the Investigator would make the subject unsuitable for the trial.
  18. Pregnant, planning to become pregnant during the trial, or breastfeeding woman. For France only: including as further defined by French Health Code L-1121-5.
  19. For France only: Any subject considered to be "vulnerable" on account of, e.g., mental or physical disability, socio-economic situation, or subjects deprived of their liberty. For France only: including as further defined by French Health Code L1121-8-1.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Molgramostim

Double-blind treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 48 weeks

Molgramostim 300 µg nebulizer solution

Autres noms:
  • Facteur recombinant humain de stimulation des colonies de granulocytes-macrophages (rhGM-CSF)
Comparateur placebo: Placebo

Double-blind treatment with placebo (PBO) nebulizer solution once daily for 48 weeks

Matching placebo nebulizer solution

Autres noms:
  • Nébuliseur placebo
Expérimental: Molgramostim Open-label Extension

Open-label treatment with molgramostim nebulizer solution 300 µg once daily (Mol OD) for 96 weeks

Molgramostim 300 µg nebulizer solution

Autres noms:
  • Facteur recombinant humain de stimulation des colonies de granulocytes-macrophages (rhGM-CSF)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24
Délai: From Baseline to Week 24

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj).

From Baseline to Week 24

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change From Baseline in Percent (%) Predicted DLCO Adjusted for Hemoglobin Concentration (%DLCOadj) to Week 48
Délai: From Baseline to Week 48

As a measure of pulmonary gas transfer, a standardized lung function test, DLCO, was conducted. The single-breath DLCO test was performed in accordance with American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines for DLCO testing. Results reported as % predicted DLCO adjusted for hemoglobin concentration (%predicted DLCOadj). Higher values indicate better respiratory gas exchange.

From Baseline to Week 48
Change From Baseline in St. Georges Respiratory Questionnaire (SGRQ) Total Score to Week 24
Délai: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 24
Change From Baseline in SGRQ Activity Component Score to Week 24
Délai: From Baseline to Week 24

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 24
Change From Baseline in Exercise Capacity (EC), Expressed as Peak Metabolic Equivalents (METs) to Week 24
Délai: From Baseline to Week 24

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 24
Change From Baseline in SGRQ Total Score to Week 48
Délai: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) is designed to measure respiratory health impairment. The scale includes questions related to three components: Activity (activities that cause or are limited by breathlessness), Impact (social functioning and psychological disturbances resulting from airway disease), and Symptoms (respiratory symptoms, their frequency and severity). The questionnaire has a recall period of 4 weeks for Symptoms, whereas Activity and Impact components address the subject's current state. SGRQ scored on a 0-100 scale with lower scores indicating better respiratory health.

From Baseline to Week 48
Change From Baseline in SGRQ Activity From Baseline to Week 48
Délai: From Baseline to Week 48

The Saint Georges Respiratory Questionnaire (SGRQ) Activity scale is a subscale of the SGRQ and is designed to measure the effect of respiratory health impairment on daily activity affected by breathlessness. The questionnaire for the Activity components addresses the subject's current state. SGRQ Activity is scored on a 0-100 scale with lower scores indicating better respiratory health activity

From Baseline to Week 48
Change From Baseline in EC, Expressed as Peak METs to Week 48
Délai: From Baseline to Week 48

As a functional measure of exertional limitations related to dyspnea, EC was assessed by an exercise treadmill test. EC was expressed in peak METs (1 MET=3.5 mL O2/kg/min). The highest treadmill speed and grade achieved was used to calculate peak METs. Higher values indicate better functional capacity.

From Baseline to Week 48
Change From Baseline in Alveolar-arterial Oxygen Difference (A-aDO2) to Week 24 (All Subjects)
Délai: From Baseline to Week 24

A-aDO2 was used as an additional measure of gas exchange.

From Baseline to Week 24
Number of Subjects With Serious and Non-serious Adverse Events
Délai: From Baseline until End of Double-blind treatment (Week 48)

Assessment of the safety of molgramostim compared to placebo

From Baseline until End of Double-blind treatment (Week 48)
Number of Subjects With Positive Treatment-boosted Anti Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Antibody Titers During 24 Weeks' Treatment and During 48 Weeks' Treatment
Délai: From Baseline until End of Double-blind treatment Week-48

Assess the effect of molgramostim or placebo on antiGM-CSF antibody titers that increased by a dilution factor of 2.(4X increase in titer compared to Baseline).

From Baseline until End of Double-blind treatment Week-48
Changes in Forced Vital Capacity (FVC) %Predicted Normal
Délai: From Baseline to Weeks 24 and 48

Forced vital capacity is the volume of air that can be expired after a deep breath. Higher volumes indicate better respiratory function. FVC is scored as % of predicted normal expired vital capacity.

From Baseline to Weeks 24 and 48
Changes in Forced Expiratory Volume in One Second (FEV1) % Predicted Normal.
Délai: From Baseline to Weeks 24 and 48

FEV1 is the volume of air expired in 1 second in liters (L). Higher values indicate better respiratory function.

From Baseline to Weeks 24 and 48
Change in QT Interval Corrected by Fridericia (QTcF)
Délai: From Baseline to Weeks 4 and 24

Assessment of the safety of MOL compared to placebo

From Baseline to Weeks 4 and 24

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Bruce Trapnell, MD, Children's Hospital Medical Center, Cincinnati

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 mai 2021

Achèvement primaire (Réel)

30 novembre 2023

Achèvement de l'étude (Estimé)

30 mai 2027

Dates d'inscription aux études

Première soumission

3 septembre 2020

Première soumission répondant aux critères de contrôle qualité

3 septembre 2020

Première publication (Réel)

10 septembre 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Mots clés

Autres numéros d'identification d'étude

  • SAV006-05
  • 2020-001263-85 (Numéro EudraCT)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .